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Abstract: The role of thalidomide has been well established in the setting of relapsed or 
refractory multiple myeloma (MM). More recently, studies have been focused on upfront induc-
tion therapy. In newly diagnosed MM patients, thalidomide improved the response rates and 
the event-free survival induced by both high-dose and conventional chemotherapy regimens. 
The effect on survival needs to be further investigated. The efﬁ  cacy of this drug is counterbal-
anced by a signiﬁ  cant rate of both acute and long-term toxicities. Thus best timing of initiation, 
dosing schemes and duration of therapy is still unclear. Evidence is now emerging that clinical 
response can be achieved also at lower doses with minimal long term toxicity.
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Introduction
Multiple myeloma (MM) is an incurable malignancy of terminally differentiated 
B-cells accounting for approximately 1 to 2% of all human cancers (Cohen et al 
1998). Patients treated with conventional chemotherapy have a median survival of 
3 to 4 years (San Miguel et al 1999). The use of high-dose chemotherapy (HDT) 
followed by autologous or allogeneic transplantation of hematopoietic stem cells has 
improved the outcome and survival and is now considered the standard of care for 
symptomatic MM patients younger than 65 years with good performance status (Attal 
et al 1996; Child et al 2003). Response rate and survival are doubled with HDT, but 
relapse still occurs. Although HDT is a relatively safe procedure with a low mortality 
rate in experienced centers, many patients are not eligible for the procedure because 
of advanced age or the presence of co-morbidities (Harousseau et al 2002). Intermit-
tent melphalan plus prednisone (MP) therapy is considered the standard treatment 
for the majority of elderly patients. MP is used worldwide with response rates of 
about 50% and a median overall survival (OS) of 2–3 years (Alexanian et al 1969). 
In the last decade promising results have been reported in elderly patients with new 
therapeutic drugs.
The activity of thalidomide as single agent in refractory or relapsed MM has been 
ﬁ  rst reported in 1999 (Singhal et al 1999); numerous phase II trials have further con-
ﬁ  rmed its activity. Response rate was signiﬁ  cantly increased when thalidomide was 
combined with dexamethasone (45–75%) (Weber et al 1999; Dimopoulos et al 2001; 
Palumbo et al 2001;Anagnostopoulos et al 2003) and with chemotherapy (67–79%) 
(Moehler et al 2001; Gonzales-Porras et al 2003; Hussein et al 2003; Kropff et al 
2003; Lee et al 2003; Dimopoulos et al 2004). The Food and Drug Administration 
has recently approved the use of thalidomide in combination with dexamethasone for 
the treatment of newly diagnosed MM patients. It has been shown that thalidomide 
acts through several mechanisms: direct pro-apoptotic effects and G1 growth arrest 
of multiple myeloma cells; down-regulation of binding of multiple myeloma cells 
to bone marrow stromal cells (BMSCs), which confers cell adhesion-mediated drug Therapeutics and Clinical Risk Management 2007:3(4) 544
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resistance (CAM-DR); and inhibition of multiple myeloma 
growth factors including IL-6, TNFα, and vascular endo-
thelial growth factor (VEGF) (Hideshima and Anderson 
2002; Hideshima et al 2002). Antiangiogenic effects are 
mediated via inhibition of VEGF and beta ﬁ  broblast growth 
factor (FGF) (Gupta et al 2001). The immunomodulatory 
effects of thalidomide has been evidenced by the upregula-
tion of natural-killer cells through the release of interferon 
gamma and IL-2, in both preclinical studies and in MM 
patients (Davies et al 2001; Lentzsch et al 2003). Based on 
its anti-inﬂ  ammatory effects thalidomide has been used in 
erithema nodosum leprosum and it is also being investigated 
for treating symptoms of prostate cancer, glioblastoma, 
lymphoma, arachnoiditis, Behçet’s disease, and Crohn’s 
disease. In recent trials, thalidomide has been incorporated 
in the front-line therapy of newly diagnosed MM patients; 
this will constitute the subject of this review.
Search strategy and selection 
criteria
PubMed was searched for references from 1999 to november 
2006, in English only with the terms “thalidomide”, “newly 
diagnosed multiple myeloma”, “new drugs for myeloma”, 
“conventional chemotherapy”. Published papers, proceedings 
from the American Society of Hematology and the American 
Society of Clinical Oncology were evaluated and are cited 
when signiﬁ  cant data were found.
Role of thalidomide in the treatment 
of smoldering or indolent MM
Smoldering/indolent myeloma constitutes approximately 
15% of all newly diagnosed cases of MM (Dimopoulos et al 
1993, 2000). Patients are generally asymptomatic; however 
the rate of progression is approximately 25% per year, with a 
median time to progression of approximately 3 years. Standard 
treatment options for smoldering/indolent MM are limited to 
observation or investigational therapy within a clinical trial 
(Kyle and Greipp 1980; Hjorth et al 1993). Patients with 
risk factors for progression to symptomatic disease, such as 
increase number or proliferative rate of circulating plasma 
cells, elevated bone marrow plasma cell labeling index, IgA 
isotype, serum M component greater than 3 g/dL or urinary M 
protein greater than 50 mg/d and abnormal magnetic resonance 
imaging of the spine may be candidates to start therapy to delay 
or prevent progression. Two phase II trials have evaluated 
single-agent thalidomide in patients with asymptomatic MM 
(Rajkumar et al 2001, 2003; Weber et al 2003). In both studies 
thalidomide was started at 200 mg dose/daily with dose escala-
tions to a maximum of 600 mg and 800 mg respectively; the 
median maximum tolerated dose was 400 mg in both studies. 
In the study conducted at the Mayo Clinic 31 patients were 
treated and 29 were evaluated. Partial responses (PR) (>50% 
reduction in serum and urine M-component) were noted in 
10 (34%) patients, with the inclusion of minor responses 
the response rate was 66%. In this study thalidomide was 
continued in responding patients at a maximum dose of 200 
mg, with several patients maintaining responses at lower doses 
of 50–100 mg/d. Overall survival (OS) at 2 years was 96% 
(Rajkumar et al 2003).
Another study conducted at the MD Anderson Cancer 
Center (MDACC) evaluated 28 patients, and the overall 
response rate was 36%. After a median follow-up of 25 
months, relapse had occurred in 3 patients (Weber et al 2003). 
While the time to progression may be prolonged for those 
patients with responsive disease, premature and long-term 
therapy in asymptomatic patients may increase neurological 
toxicities and contribute to later drug resistance. Randomized 
phase III trials are needed to deﬁ  ne the role of thalidomide 
in the treatment of newly diagnosed smoldering myeloma. 
Trials involving the use of thalidomide, pamidronate and 
zolendronate are ongoing in the United States and in many 
other countries. More data on the durability of response are 
needed before recommending this strategy for standard clini-
cal practice.
Role of thalidomide as part of HDT
in the treatment of symptomatic newly 
diagnosed MM
Thalidomide has shown synergistic activity with dexametha-
sone in relapsed MM patients (Alexanian et al 2003), the 
combination of these 2 drugs has been recently investigated 
as induction therapy.
Phase II clinical trials have shown the activity of this 
combination for induction therapy in newly diagnosed MM 
patients (Rajkumar et al 2003; Weber et al 2003; Cavo et al 
2004; Abdelkeﬁ   et al 2005; Wang et al 2005). Thalidomide 
was administered at doses ranging from 100 mg/d to 
800 mg/d, the median maximum tolerated dose was 200 mg 
in all these studies and the median duration of treatment was 
3 to 4 months. Response-rates up to 73% were observed also 
in patients with high tumor mass (Wang et al 2005), with 
manageable toxicities, mostly skin rash, deep vein 
thrombosis (DVT), neuropathy and constipation. The results 
of a randomized phase III trial of thalidomide and Therapeutics and Clinical Risk Management 2007:3(4) 545
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dexamethasone (TD) versus dexamethasone alone has been 
recently published (Rajkumar et al 2006). Response rates 
were higher in the thalidomide arm (63% v 41%, p = 0.0017), 
but a higher incidence of adverse events was observed. The 
authors recommend initial single-agent high-dose 
dexamethasone, with the addition of thalidomide later in 
lower risk patients, as an alternate approach, with the com-
bined therapy reserved for those patients with advanced 
disease and high risk features at presentation. A recent ret-
rospective analysis compared TD to VAD as induction 
therapy before high-dose therapy and autologous stem cell 
transplantation (Cavo et al 2005). TD resulted in both a 
signiﬁ  cantly higher response rate (76% v 52%, respectively) 
and a greater reduction in monoclonal proteins. Furthermore 
thalidomide did not compromize the ability to harvest 
autologous peripheral blood stem cells (PBSC) in this study 
and others. A retrospective study addressed speciﬁ  cally this 
issue; the total number of CD34 cells collected was not 
affected by previous duration or dose of thalidomide, or 
duration between thalidomide cessation and mobilization 
(Ghobrial et al 2003), while in another study the median 
number of CD34 was affected by the time from thalidomide 
discontinuation (Abdelkeﬁ   et al 2005). Long-term outcome 
after TD is not possible to ascertain in these studies, since 
the studies were intended to examine the TD regimen as a 
pretransplant induction therapy. Ongoing, larger multicenter 
studies will provide more information on progression-free 
survival and overall survival post-TD. The combination of 
TD with the proteasome inhibitor bortezomib (V) had 
induced remission in 55% of patients with myeloma resistant 
to standard therapies (Zangari et al 2005). The VTD com-
bination has been evaluated as induction treatment for 
previously untreated MM patients at the MDACC; 
bortezomib was given at 3 different doses, 1.3 mg/m2 (15 
patients), 1.5 mg/m2 (11), and 1.6 mg/m2 (10), with 
thalidomide at a maximum dose of 200 mg and pulsed oral 
dexamethasone (20 mg/m2 days 1–4, 9–12 and 17–20), 
leading to an overall response rate of 78% and a manageable 
toxicity proﬁ  le (Wang et al 2005). The combination of 
thalidomide with chemotherapy has also been widely 
evaluated. Two small studies have evaluated the association 
of thalidomide at doses ranging from 200 mg to 400 mg 
with different chemotherapeutic agents, leading to similar 
results in terms of overall response rates (up to 81%) (Zervas 
et al 2004; Schutt et al 2005). In both studies stem cell 
collection could be performed successfully. Another phase 
II trial evaluated the AD-TD combination in 45 newly 
diagnosed patients (Hassoun et al 2005). In this study 
doxorubicin and dexamethasone were given for 2 or 3 
months followed by TD for 2 months. The overall response 
rate was 84% with minimal treatment related morbidity. A 
large trial, the HOVON-50/GMM-HD3, is being conducted 
to evaluate whether thalidomide as part of induction therapy 
before and as maintenance after intensive treatment improves 
response rate, event-free (EF) and overall survival (OS). 
The standard treatment arm comprized 3 cycles of VAD, 
mobilization with CAD+G-CSF (cyclophosphamide; adria-
mycin; dexamethasone; G-CSF until end of harvest), HDT 
with 1 or 2 cycles of melphalan 200 mg/m2, followed by 
autologous peripheral blood SCT (PBSCT), and mainte-
nance with interferon-alpha (9 MU per week). In the 
experimental arm, TAD (thalidomide, 200 mg for HOV-
ON/400 mg for GMMG; adriamycin; dexamethasone 40 
mg) was used for induction treatment. Mobilization and HDT 
were identical to the standard arm. Experimental mainte-
nance was thalidomide (50 mg per day). Preliminary results 
are available for a ﬁ  rst group of 406 patients (of 1050 in-
cluded) that are evaluable for the comparison of VAD v TAD 
and response after 1st HDT. TAD induced a signiﬁ  cant 
higher response rate (80% v 63%, p = 0.001), but this effect 
was completely offset by HDT (overall response rate 91% 
v 88%, p = 0.4). No data are currently available on EFS and 
OS (Goldschmidt et al 2005). The Southwest Oncology 
Group (SWOG) embarked on a trial (SWOG 0204) of TD 
induction, modest-dose cyclophosphamide for PBSC mo-
bilization, melphalan (MEL)-based tandem autotransplant 
and subsequent prednisone-thalidomide maintenance. Pre-
liminary data on this study suggest that TD for induction 
starting at 50 mg of thalidomide and incrementing by 50 mg 
weekly to a target dose of 400 mg is well tolerated and allows 
for all patients to receive autotransplant in a timely fashion 
with no increase in toxicity. Longer follow-up will eventually 
provide information on survival (Hussein et al 2005). The 
combination of thalidomide and dexamethasone has been 
also evaluated as consolidation treatment in a small study 
at the MDACC. Twenty-one patients with stable PR after 
HDT received the TD (thalidomide 100 mg to a maximum 
dose of 300 mg) for a median of 3 months and patients with 
a marked reduction of MM markers were maintained on 
thalidomide alone until disease progression. This combina-
tion further reduced tumor mass markedly in 57% of patients 
with stable, residual disease after myeloablative therapy. 
The authors conclude that such an effect may produce longer 
disease-free survival and/or preserve tumor sensitivity to 
later retreatment with previously effective drugs (Alexanian 
et al 2002). Small studies have evaluated the feasibility of Therapeutics and Clinical Risk Management 2007:3(4) 546
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maintenance therapy with thalidomide and suggested that 
such a treatment may improve survival (Brinker et al 2006; 
Sahebi et al 2006). The UK Myeloma Forum group exam-
ined the long-term tolerance of single agent thalidomide as 
maintenance therapy after HDT. Thalidomide was evalu-
ated at 5 doses (50 mg, 100 mg, 200 mg, 250 mg, 300 mg) 
starting 3 months post HDT. There was an improvement in 
progression free survival (PFS) for those who managed to 
tolerate thalidomide for at least 6 and preferably 12 months. 
Only 8% of patients sustained a dose of 300 mg. Side effects, 
particularly peripheral neuropathy, led to discontinuation in 
2 thirds of patients at a median follow up of 23.5 months. 
The best outcome was seen in patients who achieved a CR 
only after the initiation of thalidomide (Feyler et al 2005). 
Two large studies have provided data on survival with tha-
lidomide as part of upfront treatment in multiple myeloma 
patients undergoing HDT. One has been recently published 
by Barlogie and colleagues (2006) from the University of 
Arkansas. This was a large randomized trial conducted on 
668 patients between October 1998 and February 2004. At 
enrollment, patients were randomly assigned either to a 
control group (no thalidomide) or to experimental group 
(thalidomide). The thalidomide doses were 400 mg daily 
during induction chemotherapy (withheld on day 5 of cycle 
3 of chemotherapy for the PBSC collection), 100 mg daily 
between transplantations, 200 mg daily with consolidation 
therapy, 100 mg daily during the ﬁ  rst year of maintenance 
therapy, and then 50 mg on alternating days until relapse or 
occurrence of adverse events. In the experimental group a 
higher rate of complete response (CR) (62% v 43%, 
p < 0.001) and a superior 5-year EFS (56% v 44%, p = 0.001) 
were observed. The 5-year OS was approximately 65% in 
both groups (p = 0.90), with a median survival after relapse 
of 1.1 year in the thalidomide group and 2.7 years in the 
control group (p = 0.001). Barlogie and colleagues (2005) 
are currently evaluating in the Total Therapy 3 protocol the 
incorporation of bortezomib in thalidomide-chemotherapy 
based regimen for induction, consolidation and maintenance 
treatment. The other study has been conducted by The 
Intergroupe Francophone du Myelome (IFM). In this study 
patients withouth progressive disease 2 months after the 
second transplant were randomized to receive: no mantein-
ance (Arm A), maintenance treatment with pamidronate 
(Arm B) or with thalidomide and pamidronate (Arm C). 
Thalidomide has improved the 3-year EFS (36% v 37% v 52%, 
p < 0.009), especially for those patients without chromosome 
13 deletion and beta2microglobulin >2.5 mg/dl. The 4-year 
OS was better for Arm C compared to arm B (87% v 74%, 
p < 0.003) (Attal et al 2006). Table 1 summarizes the 
prominent ﬁ  ndings of the above studies.
Thalidomide as part of conventional 
treatment for the elderly MM patients or 
for patients not candidates to HDT
For elderly MM patients conventional chemotherapy 
has remained the treatment of choice since 1960. The TD 
combination has been proven effective in a small study 
inducing an overall response rate of 48% with a median 
time to disease progression of 18 months (Dingli et al 2005). 
The combination of thalidomide with conventional dose 
chemotherapy can further improve response as shown with 
the ThaDD combination. The ThaDD regimen consisted of 
Thalidomide 100 mg/day, pegylated liposomal doxorubicin 
40 mg/m2 on day 1 and dexamethasone 40 mg days 1–4, 
9–12; the overall response rate was 89%, with a 2-yr EFS 
and OS of 65% and 70% respectively (Ofﬁ  dani et al 2006). 
The combination of thalidomide, cyclophosphamide and 
pulsed dexamethasone (CTD) was effective in refractory/
relapsed patients (Garcia-Sanz et al 2002; Dimopoulos et al 
2004). The Medical Research Council (MRC) Myeloma IX 
trial is currently comparing in the non intensive pathway the 
melphalan-prednisone (MP) regimen to an attenuate version 
of the CTD. The CTD combination (oral cyclophosphamide 
500 mg, days 1, 8 and 15, thalidomide at a maximum dose 
of 200 mg and oral dexamethasone 40 mg, days 1–4 and 
15–18) was found to be very effective in a group of 15 
patients (Williams et al 2004). Higher rates of complete 
response approaching the rates observed with HDT plus 
stem cell transplantation have recently been found in trials 
of thalidomide combined with standard treatment with mel-
phalan and steroids (Palumbo et al 2005, Dimopoulos et al 
2006; Palumbo et al 2006). In the study of Dimopoulos and 
colleagues (2006), thalidomide at the ﬁ  xed dose of 300 mg 
(days 1–4 and 14–18) was associated with oral melphalan 
(8 mg/m2, days 1–4) and pulsed dexamethasone (12 mg/
m2, days 1–4 and 14–18), for 3 courses, and followed by 
additional 9 courses where the 3 drugs where given at the 
same doses on days 1–4 only. The overall response rate was 
72%, with a median time to progression of 21.2 months and 
a median OS of 28.2 months (Dimopoulos et al 2006). A 
prospective, multicenter randomized trial of oral MP with 
or without thalidomide for the treatment of patients with 
newly diagnosed MM age > 65 years was initiated. Patients 
were randomly assigned to receive oral MP (Melphalan 4 
mg/m2, days 1–7; prednisone 40 mg/m2 days 1–7) with or Therapeutics and Clinical Risk Management 2007:3(4) 547
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without thalidomide (100 mg per day continuously until 
any sign of relapse or progressive disease). Higher response 
rates (76% v 47.6%) and longer 2 year EFS (54% v 27%) 
were observed in the experimental arm, but longer follow-
up is needed to assess effect on OS (Palumbo et al 2006). In 
another trial patients were randomized to TD (thalidomide 
200 mg/day, dexamethasone 40 mg, days 1–4 and 15–18 on 
odd cycles and days 1–4 on even cycles) or MP (melphalan 
2.5 mg/kg day 1–4 and P 2 mg/kg days 1–4, q 4–6 weeks). 
The interim analysis showed a higher response rate and 
a signiﬁ  cantly shorter time to response in the TD group 
(Ludwig et al 2005).
In May 2000, the IFM initiated a new trial, IFM 99–06, 
for patients aged 65–75 years, comparing MP (12 courses 
at 6 weeks intervals) to MPT (MP plus thalidomide at the 
maximum tolerated dose, 400 mg/day, but stopped at the end 
of MP) and a MEL100-based treatment (intermediate-dose 
MEL). The PFS time was signiﬁ  cantly longer in the MPT 
group than in the MP group (hazard ratio estimate, RR = 2.4, 
95% CI = 1.8–3.3, P < 0.0001), but no signiﬁ  cant difference 
was noted between MP and MEL100 groups (RR = 1.2, 
P = 0.12). In the secondary PFS comparison, there was a 
clear advantage in favor of MPT v MEL 100 (RR = 2.0, 95% 
CI = 1.4–2.8, P = 0.0001). The PFS advantage in favor of MPT 
group translated to a signiﬁ  cant beneﬁ  t in terms of OS. The OS 
time was signiﬁ  cantly longer in MPT group than in MP group 
(RR = 1.9, 95% CI = 1.3–2.9, P = 0.0009), but not signiﬁ  cantly 
different between MP and MEL100 groups (RR = 1.2, P = 
0.38). In the secondary OS comparison, superiority of MPT 
on MEL100 was evidenced (RR = 1.7, P = 0.022). The au-
thors suggest that MPT should be considered the reference 
treatment for newly diagnosed MM patients ineligible for 
high-dose therapy (Facon et al 2005). The combination of 
bortezomib with thalidomide and/or conventional chemo-
therapy regimens has shown promising results in phase II 
trials on relapsed patients (Palumbo et al 2005; Terpos et al 
2005; Berenson et al 2006). The Spanish Myeloma Group 
has recently published data from a phase I/II trial in which 
patients ineligible for HDT were treated with standard MP 
and bortezomib; the overall response rate was 89%, with 
32% CR (Mateos et al 2006). Data from the multicenter in-
ternational randomized trial VISTA, that has completed the 
accrual of patients, are not available yet. Table 2 summarizes 
the prominent ﬁ  ndings of the above studies.
Toxicity proﬁ  le
An important matter in the studies that have evaluated 
thalidomide as front-line therapy for newly diagnosed MM 
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Front-line thalidomide for myeloma
patients concerns its dose- and the duration-related toxicity. 
Single agent thalidomide has been used in SMM/indolent 
MM at doses ranging from 200 mg to 800 mg, with frequent, 
mild, short term, reversible side effects, that were gener-
ally manageable with appropriate dose reduction. The most 
common adverse events included skin rash, sedation, con-
stipation, peripheral neuropathy and fatigue (Rajkumar et al 
2001, 2003; Weber et al 2003). In symptomatic myeloma 
patients thalidomide has been associated with chemother-
apy, leading to an increased incidence of serious adverse 
events. Deep-vein thrombosis and peripheral neuropathy 
were the major adverse effects of thalidomide therapy in 
all these studies, leading to thalidomide discontinuation 
and/or dose reduction (Table 3). Thalidomide given in 
combination with chemotherapy including dexamethasone 
is associated with an increased risk of thrombosis (Zangari 
et al 2002, 2004). Mechanisms that lead to an increased risk 
of DVT for MM patients who receive primary therapy with 
TD or doxorubicin based regimens are still poorly deﬁ  ned 
and probably multifactorial. No relation between age and 
DVT and response has been detected (Rajkumar et al 2006). 
This complication occurred most commonly during induc-
tion treatment, when the burden of tumor is high, reaching 
incidence up to 34% without prophylactic anticoagulation 
(Barlogie et al 2006). After observing a high incidence of 
DVT in the initial phases of these studies, prophylactic 
anticoagulation was added and the DVT incidence was 
reduced in most of those studies (Abdelkeﬁ   et al 2005; Cavo 
et al 2005; Barlogie et al 2006; Dimopoulos et al 2006). 
The optimal prophylaxis for DVT after thalidomide has not 
been clearly established. It is now recommended that DVT 
prophylaxis, with prophylactic doses of LMWH, or full-
dose anticoagulation with oral warfarin, or aspirin at doses 
from 81 mg to 325 mg per day, should be used in all patients 
starting therapy with thalidomide plus dexamethasone and 
or chemotherapy. Full-intensity warfarin and prophylactic 
doses of low molecular weight heparin (LMWH) have been 
advocated by some as preferable to aspirin, largely due to 
the inefﬁ  cacy of aspirin as DVT prophylaxis in other set-
tings (Clagett et al 1988).
Prospective, randomized studies are needed to deter-
mine the best prophylactic anticoagulation. Neuropathy 
is the most common cause of thalidomide discontinuation 
or dose reduction in newly diagnosed patients; it has been 
shown to be the major treatment-limiting toxicity affecting 
50% to 80% of relapsed patients, the severity and revers-
ibility of which have been related to both dose and duration 
of drug administration (Kumar et al 2003). In the study 
conducted by Barlogie et al (2006) peripheral neuropathy 
with a grade of more than 2 was observed in 27% of patients 
and was more common among patients at least 65 years 
old than among younger patients (29% v 20%, P = 0.02). 
Forty-one  percent of patients who were at least 65 years old 
and who were receiving thalidomide had peripheral neu-
ropathy, as compared with 17 percent of younger patients 
in the control group (P < 0.001). Peripheral neuropathy 
improved to less than grade 2 within three to four months 
after a dose reduction or cessation of thalidomide in nearly 
Table 3 DVT and pheripheral neuropathy in newly diagnosed patients treated with thalidomide
Trial   DVT   DVT prophilaxis (Y/N)  Peripheral neuropathy 
 (%)    (%)   
Phase II (Rajkumar et al 2002)  12  N  2 (grade 3–4)
Phase III (Rajkumar et al 2006)  17  N  7 (grade 3–4)
Phase II (Wang et al 2005)  7  Y  4 (grade 3–4)
Phase II (Abdelkeﬁ   et al 2005)  3  Y (after the ﬁ  rst 13 patients)  5 (grade 3–4)
Phase II (Cavo et al 2005)  15  Y (after the ﬁ  rst 19 patients)  4 (grade 3–4)
Phase II (Zervas et al 2004)  10  N  2.5 (grade 3–4)
Phase II (Schutt et al 2005)  26  N  26 (grade not known)
Phase II (Hassoun et al 2005)  11  Y  –
Phase III (Barlogie et al 2006)  30  Y (after the ﬁ  rst 162 patients)  27 ( grade 2)
Phase III (Goldschmidt et al 2005)  8 Y  –
Phase II (Dimopoulos et al 2006)  9  N  9 (grade 2)
Phase III (Palumbo et al 2006)  12  Y (after the ﬁ  rst 65 patients)  8 (grade 3–4)
Phase II (Ofﬁ  dani et al 2005)  12 Y  0
Phase II (Wang et al 2005)  5  Y  8 (grade 3)
Phase III (Ludwig et al 2005)  20  N  19 (grade 2–3)
Phase II (Alexanian et al 2002)  0 N  14
Phase II (Sahebi et al 2006)  0 N  7
Phase II (Brinker et al 2006)  0 N  4
Phase II (Dingli et al 2005)  0  N  5Therapeutics and Clinical Risk Management 2007:3(4) 550
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